NS Pharma, Inc.
9 Campus Drive
3rd Floor
Parsippany
New Jersey
07054
United States
Tel: 973-285-7010
Fax: 973-267-4240
Website: http://www.nippon-shinyaku.co.jp/
30 articles about NS Pharma, Inc.
-
NS-018, an Investigational Treatment for Myelofibrosis, Receives Orphan Drug Designation from the European Commission
8/8/2023
NS Pharma, Inc. announced today that the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).
-
FDA Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
8/7/2023
NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
-
FDA Grants Breakthrough Therapy Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
7/27/2023
NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
-
FDA Grants Rare Pediatric Disease Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
7/7/2023
NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Rare Pediatric Disease Designation to NS-089/NCNP-02 (brogidirsen) an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
-
NS Pharma Announces FDA Clearance to Initiate a Phase I/II Study for NS-050/NCNP-03, an Exon 50 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy
6/15/2023
NS Pharma, Inc. announced the U.S. Food & Drug Administration has agreed to the planned Phase I/II study of NS-050/NCNP-03, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 50 skipping therapy.
-
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published in the Journal of Neuromuscular Diseases
5/9/2023
NS Pharma is pleased to announce that previously reported long-term efficacy and safety data (final visit up to Week 216) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) have been published in the May issue of the Journal of Neuromuscular Diseases.
-
NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy
4/14/2023
NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has agreed to the planned Phase II study of NS-089/NCNP-02 for Duchenne muscular dystrophy.
-
VILTEPSO® (viltolarsen) injection Open Label Extension Clinical Trial Data Scheduled for Presentation at the MDA Clinical & Scientific Conference 2023
3/19/2023
NS Pharma is pleased to announce participation in the Muscular Dystrophy Association's Clinical & Scientific Congress 2023 being held in Dallas, Texas. The company will be presenting previously reported long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO®.
-
NS Pharma Announces First Patient Enrolled in Phase 2 Study to Assess Efficacy and Safety of NS-018 Compared to Best Available Therapy (BAT) in Patients With Myelofibrosis
2/17/2023
NS Pharma, Inc. announced the first patient enrollment in a Phase 2 clinical study of NS-018, an investigational treatment for myelofibrosis, a rare and incurable blood cancer.
-
NS Pharma opens new U.S drug discovery center in Cambridge, MA
1/6/2023
NS Pharma announced the opening of a new office in Cambridge, Massachusetts, to establish the NS Pharma Innovation Research Partnering division.
-
NS Pharma Announces Receipt of Orphan Drug Designation from the U.S. FDA for NS-018, an Investigational Treatment for Myelofibrosis
12/20/2022
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), today announced that the U.S. FDA has granted Orphan Drug Designation to NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer.
-
NS Pharma Reports on Results of VILTEPSO® (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy
10/24/2022
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) announced today that long-term efficacy and safety data (final analysis up to Week 216) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) injection were presented at the 27th International Hybrid Annual Congress of the World Muscle Society (WMS 2022) in Halifax, Nova Scotia, Canada.
-
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference
10/4/2022
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka ), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai ), announced today that four-year efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO ® (viltolarsen).
-
The FDA lifted the clinical hold on Dyne Therapeutics’ clinical study of DYNE-251 in Duchenne muscular dystrophy (DMD) patients amenable to skipping exon 51. A Phase I/II trial is expected by mid-year.
-
VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases
5/31/2022
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced the publication of long-term efficacy and safety data based on analyses at 109 weeks from the 192-week open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection in the Journal of Neuromuscular Diseases.
-
VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting
9/22/2021
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the Child Neurology Society 50th Annual Meeting.
-
VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference
9/17/2021
NS Pharma, Inc. announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the World Muscle Society 2021 Virtual Conference being held September 20–24.
-
VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference
7/1/2021
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced that new long-term efficacy and safety data based on interim analyses at 109 weeks from the open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection were presented at the PPMD 2021 Annual Conference.
-
Webcast of VILTEPSO® (viltolarsen) injection: Long-Term Data Scheduled for Presentation at the PPMD 2021 Virtual Annual Conference
6/21/2021
NS Pharma, Inc. announces a webcast during the PPMD 2021 Virtual Annual Conference held from June 23 to 26 .
-
VILTEPSO® (viltolarsen) injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference
5/12/2021
NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced that new, long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO® injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26.